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Abstract: Actinic keratoses (AKs) are common lesions on chronically sun damaged skin, which are
morphologically characterized by lower third to full thickness atypia of epidermal keratinocytes.
These lesions carry a risk of progression towards invasive squamous cell carcinoma (SCC); therefore,
treatment of visible lesions and the field in case of field cancerization is recommended. Treatment of
AK includes the destruction of atypical keratinocytes that clinically presents with various degrees of
erythema, scaling, crusting, erosion, and other visible and subjective symptoms. Such inflammatory
reactions may have an impact on the patient’s social life and have shown to decrease compliance and
adherence to therapy. Additionally, as various topical treatments have been proven to be effective
in treating AK, tolerability of local site reactions (LSRs) might drive the decision for appropriate
treatment in an individual scenario. Therefore, we aimed to review prevalence of severe LSRs among
various topical treatments for AK. In addition, we summarized discontinuation rates due to LSRs
and possible therapy-unrelated risk factors for the development of LSRs with increased severity.
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1. Introduction
Actinic keratosis (AK) is one of the most common dermatological complaints in fair skinned
individuals that represents the cumulative UV damage of epidermal keratinocytes. On clinical
examination, AKs are variably thick and erythematous, poorly demarcated, and sometimes pigmented
lesions on chronically sun-exposed skin [1]. Prevalence steadily increases with age and a recent Swiss
study found that AK occurred in 25.3% of outpatients in general practice [2]. The clinical significance of
AKs relies on the associated discomfort, cosmetic burden, and the possibility of progression to invasive
squamous cell carcinoma (SCC). The traditional view considers that progression towards invasive
SCC requires full thickness epidermal atypia, which is clinically usually characterized by thick and
obvious lesions [3,4]. Nevertheless, a more recent study has shown that AK grade I, morphologically
characterized by atypical keratinocytes in the lower third of the epidermis, is the most common type of
AK overlying cutaneous invasive SCC [5]. This finding supports the understanding that all AKs require
treatment. However, treatment is targeted towards the destruction of atypical keratinocytes, resulting
in temporary inflammatory reactions with varying severity. Discussing the treatment-associated local
site reactions (LSRs) before therapy may lead to delay in treatment initiation. During treatment, such
reactions cause distress [6] and impact health-related quality of life [7]. A study by Strohal et al. [8]
showed that 19.4% of patients treated with imiquimod 5% cream, scheduled unplanned visits due
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to their concern of LSRs. Moreover, LSRs lead to nonadherence, thus possibly reducing treatment
efficacy [9]. As topical therapy is easy to use and a highly effective treatment modality for AK,
we aimed to systematically search the PubMed database to review prevalence of severe LSRs among
various topical treatments for AK. In addition, we summarized discontinuation rates due to LSRs and
possible therapy-unrelated risk factors for the development of LSRs with increased severity. We did
not review studies involving special equipment as conventional photodynamic therapy. For this
review, “LSRs” included visual parameters such as, but not limited to, erythema, oedema, and erosions,
and patient-reported subjective symptoms, such as pain and itching.
2. Severe Local Site Reactions with Topical Field Treatment for Actinic Keratosis of the Face
and Scalp
2.1. Prevalence of Severe Local Site Reactions
The prevalence of severe LSRs among various topical field treatment options is summarized in
Table 1 [10–28].
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187 Once daily for up to12 weeks 92.0% 27.8% **
Stough et al. [18] 2008 5-fluorouracil0.5% 277
Once daily for up to
4 weeks 87.0% 19.1% NR
NR—not reported; DL-PDT—daylight photodynamic therapy; MAL—methyl aminolevulinate; * Prevalence of the
highest symptom reported; ** Combined data of severe symptoms.
Imiquimod. Among all topical therapies, the highest prevalence of severe LSRs was reported in
studies with imiquimod 5% [24] and imiquimod 3.75% [14], with treatment regimens not commonly
used. The suggested treatment regimen for imiquimod 5% is three times per week for four weeks
followed by four weeks of rest and a second cycle if needed. Such a regimen was used in three of
the included studies, and reported the highest values of 31.0% [27] and 31.8% [26] for prevalence
of severe erythema and 8.8% prevalence of severe scabbing or crusting [25]. In the last study by
Rivers et al. [25], severe erythema was noted in 5% of patients. Such less frequent prevalence is
probably due to study methodology as patient assessment was performed at baseline and at week
8. Comparatively lower 25.2% prevalence of severe erythema and 33.8% prevalence of any severe
LSR was reported by Swanson et al. [13] with imiquimod 3.75% in two identical studies randomized
to placebo.
Ingenol mebutate. Studies with ingenol mebutate gel 0.015% (IngMeb) mostly use composite
scores to assess severity of LSRs. Each of six LSR parameters—erythema, flaking/scaling, crusting,
swelling, vesiculation/pustulation, and erosion/ulceration is graded from 0 to 4, giving a maximum
composite score of 24 [15,29]. Jim On et al. [16] reported data of two multicenter, randomized,
parallel-group, double-blind, vehicle-controlled studies, involving face and scalp and classified patients
with a composite score of 12 or higher as having a severe LSR. Thus, their reported prevalence of
severe LSRs at day 4 was 24.5%. Skroza et al. [15] included 130 patients and assessed LSRs at day 3.
The reported mean total composite scores did not allow to assess overall prevalence of severe reactions,
but they reported grade 4 swelling in 17.7% of patients. Additionally, a study by Ricci et al. [30]
reported severe pain and itching in 20.5% of treatment cycles with IngMeb. This was not included in
the chart as prevalence was calculated from treatment cycles, not patients.
5-fluorouracil. Since its approval in 1970, topical 5-fluorouracil (5-FU) has become a
well-established treatment for AK and LSRs are expected [31,32]. Three formulations − 5-FU 5%, 5-FU
0.5% and 5-FU 0.5% in combination with a salicylic acid 10% solution (5-FU/SA) are commercially
available. A prospective, open-label, multicenter study by Stough et al. [18] included 277 patients
treated with once daily application of 5-FU 0.5% cream for up to 4 weeks. Interim results of the face and
scalp showed that severe LSRs developed in 19.1% of patients. Two studies assessed efficacy and safety
of 5-FU/SA. In the first by Stockfleth et al. [10], in a randomized, placebo-controlled, double-blind,
multicenter trial conducted in Germany, low dose 5-FU/SA was compared with 3% diclofenac in 2.5%
hyaluronic acid gel (diclofenac HA). General disorders and administration-site conditions of severe
intensity were reported in 27.8% of patients in the 5-FU/SA group and in 11.9% of patients in the
diclofenac HA group. The second study by Simon et al. [20] compared 5-FU/SA with cryotherapy
and included 33 patients in each treatment arm. Severe application site reactions were reported in six
patients (18.2%) in 5-FU/SA arm and in one (3%) patient receiving cryotherapy.
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Diclofenac HA. Pflugfelder et al. [19] reported 13.6%, which is the highest prevalence of severe
LSRs in treatment with diclofenac HA. In a multicenter, randomized, open-label study with 418
included patients, they compared three-month vs. six-month treatment of actinic keratoses with
diclofenac HA. Severe LSRs developed mainly in the first weeks of treatment and longer treatment only
slightly increased the mean intensities of LSRs [19]. As already mentioned above, Stockfleth et al. [10]
in a randomized, placebo-controlled, double-blind, multicenter trial conducted in Germany, reported
general disorders and administration-site conditions of severe intensity in 11.9% of patients in diclofenac
HA group.
Daylight photodynamic therapy. Only a single study reported a severe LSR in treatment with
daylight photodynamic therapy (DL-PDT). This was a prospective, observational study conducted in
Australia by See et al. [22], and they reported a single patient with severe post-treatment phototoxic
reaction with erythema, pain, pruritus, and a skin burning sensation. This allowed a calculation of
1.2% of severe LSRs. Other studies on DL-PDT reported that none of the treated patients experienced
severe LSRs [11,21,23].
2.2. Treatment Discontinuation Due to Local Site Reactions
In total, 14 articles reported treatment discontinuation rates due to LSRs with commonly used
therapeutic regimens (Figure 1). The highest discontinuation rate of 13.6% was reported in a study
by Pflugfelder et al. [19] that compared efficacy, tolerability, and quality of life of diclofenac HA
used twice daily for three or six months. The study included 418 patients and eczematous reactions
leading to discontinuation developed mainly in the first weeks of treatment. The second study with
twice daily application of diclofenac HA was conducted by Stockfleth et al. [10] and reported a lower
4.9% discontinuation rate due to LSRs. Albeit, in this study, in the case of severe LSRs, application
frequency was allowed to be reduced to once daily. The second highest rate of discontinuation due
to LSRs was reported with 5-FU/SA by Simon et al. [20]. In the study evaluating efficacy, tolerability,
and safety of low-dose 5-FU/SA topical solution vs. cryosurgery, they reported 9.1% discontinuation
in the 5-FU/SA arm of 33 patients. As cryotherapy is a one-off treatment, it cannot be used as a true
discontinuation comparator. Two other studies with 5-FU/SA and larger sample size reported 0.9%
and 3.7% discontinuation rates [30,33]. Two studies reported discontinuation rates with low dose
5-FU cream. A study by Smith et al. [34] had 12 patients in the 5-FU 0.5% cream group, and the
discontinuation of a single patient allowed a calculation of an 8.3% discontinuation rate. A study
by Stough et al. [18] had 277 patients included and reported a discontinuation rate of 0.4%. A 5%
5-FU cream was used in one of the identified studies and included 50 patients. No discontinuations
were reported [35]. Three articles showed discontinuation rates ranging from 0.5% to 3.2% with
imiquimod 5% cream [25,27,36]. A discontinuation rate of up to 1.1% was reported in the studies with
IngMeb [17,35,37]. This highest value was due to severe erosions in one of 88 included patients [37].
Treatment discontinuation due to LSR is not a concern for DL-PDT [11,21–23,38].
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Figure 1. Reported rates of treatment discontinuation due to LSRs. Imiq 5%—imiquimod 5% cream; 
5-FU 5%—5-fluorouracil 5% cream; 5-FU 0.5%—5-fluorouracil 0.5% cream; 5-FU/SA—5-fluorouracil 
in combination with salicylic acid 10% solution; Diclof 3%—3% diclofenac in 2.5% hyaluronic acid 
gel; IngMeb 0.015%—ingenol mebutate 0.015% gel. 
2.3. Therapy-Unrelated Risk Factors for Development of Local Site Reactions with Increased Severity 
Severity of LSRs depends on the administered active ingredient and application frequency. 
Additionally, several studies have implications on patient-associated and environmental risk factors. 
Primarily, light pigmentation is a risk factor for both AK and treatment-induced severity of LSRs 
[39]. A study with IngMeb by Ricci et al. [37] with a standard patient-applied regimen of once daily 
IngMeb for three consecutive days, showed that patients with a fair skin type (phototype I–II) had 
stronger LSRs at day 4 and more erosions than patients with phototype III–IV. Moreover, although 
DL-PDT generally does not cause severe LSRs, in a study by Galvão et al. [40], moderate erythema 
after two hours of outdoor exposure was seen only in an albino patient. Other proposed risk factors 
for greater severity of LSRs with IngMeb are: the female gender, an age below 70 years, and Korean 
patients [41]. This last observation was suggested to be related to the difference of race and skin 
thickness [42]. The importance of environmental factors has been suggested in a study by Fargnoli et 
al. conducted in Italy from September to October. In particular, high outdoor temperature was 
associated with severity of LSRs and treatment efficacy of DL-PDT [38]. 
3. Conclusions 
Local site reactions of severe intensity seem to be extremely common among topical therapies 
for AK, especially with imiquimod. The only therapeutic modality with low prevalence of severe 
LSRs is DL-PDT. Treatment discontinuation due to LSRs is also common, although the highest 
prevalence of treatment discontinuation due to LSRs is reported in studies with the longest treatment 
regimens, as with diclofenac, and not in studies reporting the highest prevalence rates of severe LSRs. 
Several patient-associated risk factors for the development of severe LSRs have been identified in 
studies with DL-PDT and IngMeb. Nevertheless, to have better evidence of individual risk for severe 
LSRs, further studies could identify more risk factors, and include other therapies. 
Author Contributions: Conceptualization, A.B. and A.K.; systematic search of literature, A.B.; writing—original 
draft preparation, A.B.; writing—review and editing, A.B., M.R.K., I.Č. and AK.; visualization, A.B. 





























Treatment modality for actinic keratosis of the face and scalp
i r 1. t t f t t t i ti ti t . I i i i i r ;
- 5 5-fluorouracil 5% cream; 5-FU 0.5%—5-fluorouracil 0.5% cream; 5-FU/SA—5-fluor uracil in
combination with salicylic a id 10% solution; Diclof 3%—3% diclofenac in 2.5% hyaluronic acid gel;
IngMeb 0.015%—ingenol mebutate 0.015% gel.
2.3. Therapy-Unrelated Risk Factors for Development of Local Site Reactions with Increased Severity
Severity of LSRs depends on the administered active ingredient and application frequency.
Additionally, several studies have implications on patient-associated and environmental risk factors.
Primarily, light pigmentation is a risk factor for both AK and treatment-induced severity of LSRs [39].
A study with IngMeb by Ricci et al. [37] with a standard patient-applied regimen of once daily IngMeb
for three consecutive days, showed that patients with a fair skin type (phototype I–II) had stronger
LSRs at day 4 and more erosions than patients with phototype III–IV. Moreover, although DL-PDT
generally does not cause severe LSRs, in a study by Galvão et al. [40], moderate erythema after two
hours of outdoor exposure was seen only in an albino patient. Other proposed risk factors for greater
severity of LSRs with IngMeb are: the female gender, an age below 70 years, and Korean patients [41].
This last observation was suggested to be related to the difference of race and skin thickness [42].
The importance of environmental factors has been suggested in a study by Fargnoli et al. conducted in
Italy from September to October. In particular, high outdoor temperature was associated with severity
of LSRs and treatment efficacy of DL-PDT [38].
3. Conclusions
Local site reactions of severe intensity seem to be extremely common among topical therapies for
AK, especially with imiquimod. The only therapeutic modality with low prevalence of severe LSRs
is DL-PDT. Treatment discontinuation due to LSRs is also common, although the highest prevalence
of treatment discontinuation due to LSRs is reported in studies with the longest treatment regimens,
as with diclofenac, and not in studies reporting the highest prevalence rates of severe LSRs. Several
patient-associated risk factors for the development of severe LSRs have been identified in studies with
DL-PDT and IngMeb. Nevertheless, to have better evidence of individual risk for severe LSRs, further
studies could identify more risk factors, and include other therapies.
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